Prof. Hongjian Yang 杨红健
Chief Physician, Professor
Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast diseases, including early diagnosis, modified radical mastectomy, breast-conserving surgery, comprehensive therapy, and post-mastectomy reconstruction. Also treats limb soft tissue malignancies with limb-sparing surgery, functional reconstruction, and repair of large tissue defects.
Dr. Yang is Chief Physician and Professor at Zhejiang Cancer Hospital, heading Ward 9. Graduating from Zhejiang University School of Medicine in 1986 with a master's degree, Dr. Yang completed further training in Israel (2008–2009). Research focuses on breast cancer surgery timing, sentinel lymph node navigation, and quantitative models for adjuvant therapy. Dr. Yang has published over 60 papers.
Professional roles
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Breast Cancer Professional Committee, Zhejiang Anti-Cancer Association
- Member, Oncologic Surgery Branch, Zhejiang Medical Association
- Editorial Board Member, Chinese Journal of Cancer
Name order: in Chinese the family name comes first (Yang Hongjian). Papers usually list the name as Hongjian Yang or Yang H.
Selected publications
80 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2021 (senior author): Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World. PubMed 34395277
- Clin Breast Cancer, 2020 (senior author): Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer. PubMed 32414649
- Cancer Chemother Pharmacol, 2020 (first author): Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells. PubMed 32277242
- Ann Surg Oncol, 2020 (senior author): A Prospective Validation Cohort Study of a Prediction Model on Non-sentinel Lymph Node Involvement in Early Breast Cancer. PubMed 31659631
- J Cell Biochem, 2019 (senior author): Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57(KIP2) and involving in p-p38 MAPK and NF-κB pathways. PubMed 30378143
- Cytotechnology, 2018 (senior author): Knockdown of ribosomal protein S15A inhibits proliferation of breast cancer cells through induction of apoptosis in vitro. PubMed 29802490
- ESMO Open, 2017 (senior author): The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study. PubMed 28761739
- Int J Mol Med, 2017 (senior author): ICT1 knockdown inhibits breast cancer cell growth via induction of cell cycle arrest and apoptosis. PubMed 28290601
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion